Laurène Wagner

Dr. Laurène Wagner

LCPM, Nancy, Grand Est, France
+1
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 August 2022 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Batoul DhainiBatoul Dhaini
Batoul Dhaini
Laurène WagnerLaurène Wagner
Laurène Wagner
MMMorgane Moinard
Morgane Moinard
JDJoël Daouk
Joël Daouk
MAM ARNOUX
M ARNOUX
Céline FrochotCéline Frochot
Céline Frochot
Rose Bengal (RB) is a photosensitizer (PS) used in anti-cancer and anti-bacterial photodynamic therapy (PDT). The specific excitation of this PS allows the production of singlet oxygen and oxygen reactive species that kill bacteria and tumor cells. In this review, we summarize the history of the use of RB as a PS coupled by chemical or physical means to nanoparticles (NPs). The studies are divided into PDT and PDT excited by X-rays (X-PDT), and subdivided on the basis of NP type. On the basis of the papers examined, it can be noted that RB used as a PS shows remarkable cytotoxicity under the effect of light, and RB loaded onto NPs is an excellent candidate for nanomedical applications in PDT and X-PDT.

11 May 2022 in Nanomaterials
Verified
Journal Article
Open access
PDF file
CGChloé Guilbaud-Chéreau
Chloé Guilbaud-Chéreau
BDBhimareddy Dinesh
Bhimareddy Dinesh
Laurène WagnerLaurène Wagner
Laurène Wagner
OCOlivier Chaloin
Olivier Chaloin
CMCécilia Ménard-Moyon
Cécilia Ménard-Moyon
Alberto BiancoAlberto Bianco
Alberto Bianco
Peptide-based hydrogels are considered of special importance due to their biocompatibility and biodegradability. They have a wide range of applications in the biomedical field, such as drug delivery, tissue engineering, wound healing, cell culture media, and biosensing. Nevertheless, peptide-based hydrogels composed of natural α-amino acids are limited for in vivo applications because of the possible degradation by proteolytic enzymes. To circumvent this issue, the incorporation of extra methylene groups within the peptide sequence and the protection of the terminal amino group can increase the enzymatic stability. In this context, we investigated the self-assembly capacity of aromatic dipeptides (Boc-α-diphenylalanine and Boc-α-dityrosine) and their β- and γ-homologues and developed stable hydrogels. Surprisingly, only the Boc-diphenylalanine analogues were able to self-assemble and form hydrogels. A model drug, l-ascorbic acid, and oxidized carbon nanotubes (CNTs) or graphene oxide were then incorporated into the hydrogels. Under near-infrared light irradiation, the photothermal effect of the carbon nanomaterials induced the destabilization of the gel structure, which caused the release of a high amount of drug, thus providing opportunities for photocontrolled on-demand drug release.

17 June 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Ute HennrichUte Hennrich
Ute Hennrich
Laurène WagnerLaurène Wagner
Laurène Wagner
HTHarun Taş
Harun Taş
LKLuciana Kovacs
Luciana Kovacs
Martina BenešováMartina Benešová
Martina Benešová
Locametz®/Illuccix®/GozellixTM (Novartis AG (Basel, Switzerland) and Telix Pharmaceuticals, Ltd. (Melbourne, Australia), all three [68Ga]Ga-PSMA-11), Pylarify®/Pylclari® (Progenics Pharmaceuticals, Inc. (New York, USA) and Curium PET France SA (Paris, France), both [18F]DCFPyL), Radelumin® (ABX GmbH (Radeberg, Germany), [18F]PSMA-1007), and Posluma® (Blue Earth Diagnostics, Ltd. (Oxford, UK), [18F]rhPSMA-7.3) are four approved PSMA-PET imaging agents that have significantly advanced the diagnosis and management of prostate cancer. These agents offer a new level of precision and accuracy, enabling clinicians to detect prostate cancer with enhanced sensitivity. As a result, they play a critical role in improving detection, staging, and management, ultimately enhancing clinical outcomes for patients. Their use in routine clinical practice is expected to increase diagnostic precision and provide clearer pathways for personalized therapy. This review offers a comprehensive chemical, pharmaceutical, and medicinal overview, discusses comparative studies, and highlights additional highly relevant candidates for prostate cancer detection.

4 October 2023 in Inorganic Chemistry
Verified
Journal Article
Open access
TPThomas W. Price
Thomas W. Price
Laurène WagnerLaurène Wagner
Laurène Wagner
VRVeronika Rosecker
Veronika Rosecker
JHJana Havlíčková
Jana Havlíčková
Timothy PriorTimothy Prior
Timothy Prior
GSGraeme J Stasiuk
Graeme J Stasiuk
We report here the improved synthesis of the tripodal picolinate chelator Tpaa, with an overall yield of 41% over five steps, in comparison to the previously reported 6% yield. Tpaa was investigated for its coordination chemistry with Ga(III) and radiolabeling properties with gallium-68 (Ga-68). The obtained crystal structure for [Ga(Tpaa)] shows that the three picolinate arms coordinate to the Ga(III) ion, fully occupying the octahedral coordination geometry. This is supported by H-1 NMR which shows that the three arms are symmetrical when coordinated to Ga(III). Assessment of the thermodynamic stability through potentiometry gives log KGa-Tpaa = 21.32, with a single species being produced across the range of pH 3.5-7.5. Tpaa achieved >99% radiochemical conversion with Ga-68 under mild conditions ([Tpaa] = 6.6 mu M, pH 7.4, 37 C-degrees) with a molar activity of 3.1 GBq mu mol(-1). The resulting complex, [Ga-68][Ga(Tpaa)], showed improved stability over the previously reported [Ga-68][Ga(Dpaa)(H2O)] in a serum challenge, with 32% of [Ga-68][Ga(Tpaa)] remaining intact after 30 min of incubation with fetal bovine serum.

7 April 2026
Verified
Thesis
Closed access
Laurène WagnerLaurène Wagner
Laurène Wagner
L'imagerie moléculaire, en particulier l'imagerie de tomographie par émission de positons (β+) (TEP) est devenue indispensable au diagnostic de nombreuses maladies comme les cancers. L'essor de cette technique non invasive est lié à l'obtention d'images tridimensionnelles, après injection d'un radiotraceur, permettant de localiser et quantifier des cibles spécifiques à la pathologie. Les radiotraceurs sont également employés pour le traitement de cancer par radiothérapie interne vectorisée (RTIV). Ces radiotraceurs associent majoritairement un agent de ciblage, interagissant avec un biomarqueur de la pathologie, et un agent chélatant complexant un radionucléide permettant l'enregistrement d'images. Récemment une nouvelle technique de radiomarquage au fluor-18 par chimie de complexation (i.e., formation du complexe d'aluminium-fluor-18) a vu le jour et est devenue une technique de choix pour le développement de nouveaux radiotraceurs. En fonction de la nature des agents chélatants, différents radionucléides peuvent être complexés par les traceurs. Le fluor-18 (18F) et le gallium-68 (68Ga) sont des radionucléides de choix pour l'imagerie TEP et le lutétium-177 (177Lu) pour la RTIV, mais ces trois radionucléides possèdent des propriétés de complexation différentes. Ainsi, l'aluminium-fluor-18 peut être complexé par des agents chélatants de types HBED-CC et NOTA, le gallium-68, par des agents chélatant de types HBED-CC, NOTA et DOTA et le lutécium-177, par des agents chélatant de type DOTA. L'objectif de ces travaux de thèse est de développer un nouvel agent chélatant bifonctionnel (ACB) pouvant être (i) radiomarqué à l'aluminium-fluor-18, au gallium-68et au lutécium-177 par chimie de complexation, et (ii) couplé à des peptides de ciblage. Le but est de préparer des « peptides-chélatants » pouvant être utilisés en imagerie TEP et en RTIV pour une application en théranostic (thérapie + diagnostic) s'insérant dans une démarche de médecine personnalisée. Dans un premier temps, le nouvel ACB a été synthétisé puis complexé à l'aluminium-fluor, au gallium et au lutécium (références froides). Des études de complexation ont été réalisées par RMN et par modélisation moléculaire pour montrer l'aptitude de l'ACB à complexer ces trois radionucléides. L'ACB a ensuite été couplé à des agents de ciblage connus tels que le RGD (pour le diagnostic de tumeurs surexprimant les intégrines αvβ3), le motif DUPA (pour le diagnostic du cancer de la prostate) et l'acide folique (pour le diagnostic du cancer de l'ovaire). En parallèle de ces travaux, la stratégie de radiomarquage aluminium-fluor-18, a été mise au point à Nancyclotep sur le précurseur de marquage PSMA-11 à l'aide d'une méthodologie des plans d'expériences, encore peu utilisée en radiochimie de nos jours. Enfin, le radiomarquage à l'aluminium-fluor-18 et au gallium-68 du nouvel ACB a été réalisé.